PRM-151 therapy well tolerated in patients with advanced myelofibrosis

9 diciembre 2014

A study that investigated the potential of the compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in patients with advanced myelofibrosis has shown initial positive results. Myelofibrosis is a life-threatening bone marrow cancer.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/OE8VDrN_nYI/141209081049.htm

Volver